Broncus Anticipates 2019 Completion Of EAST2 Study Of Archimedes Lung-Nodule Navigator
Executive Summary
Results from a substudy of EAST2 focused on nodules without a bronchus sign or an airway leading to the nodule shows Broncus' Archimedes system, with proprietary virtual bronchoscopic navigation and "fused fluoroscopy" technology, provides access to nodules located anywhere in the lungs without puncturing the chest wall.
You may also be interested in...
NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients
This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.
Boston Scientific Puts Charge In Neuromodulation Business By Acquiring Relievant
Relievant’s Intracept intraosseous nerve ablation system is the only FDA-cleared neuromodulation device indicated to treat vertebrogenic pain. Boston Scientific will pay $850m for Relievant, plus undisclosed milestone payments over the next three years.
News We’re Watching: Philips And Walgreens Settlements, ReCor Readies For Takeoff, Farapulse Trial Results
This week, Philips announced a legal settlement on recalled CPAPs and BiPAPs; the FDA released emergency preparation recommendations; ReCor prepared to bring Paradise RDN to the US market; and Abbott released the results of a trial comparing optical coherence tomography (OCT) to angiography for guidance during cardiac surgery.